InvestorsHub Logo
Post# of 252187
Next 10
Followers 833
Posts 119839
Boards Moderated 17
Alias Born 09/05/2002

Re: genisi post# 169412

Thursday, 11/14/2013 2:19:12 PM

Thursday, November 14, 2013 2:19:12 PM

Post# of 252187
GILD borrows a page from ABBV/ENTA in constructing a ‘Plan B’ for all-oral treatment of GT1 patients: adding a non-nuke as a third agent. Specifically, GILD just started a phase-2 trial with three choices for the addend to Sofosbuvir + Ledispavir: i) high-dose GS-9669; ii) low-dose GS-9669; and iii) ribavirin; all arms have a treatment duration of 8 weeks:

http://clinicaltrials.gov/ct2/show/NCT01984294

The trial includes 90 patients who are GT1a or Gt1b and are treatment-naïve or treatment-experienced. Results are expected in Mar 2014.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.